Led inorganic & organic strategy and cross-functional execution for a $4B business unit, aligning product strategy with operational, regulatory, and clinical goals. Architected radiopharma- and oncology-focused strategy, target engagement, and business cases integrating smart device platforms with infusion safety protocols. Advanced high-stakes initiatives from concept to governance in cross-functional alignment with technical, clinical, regulatory, and commercial leaders. Deployed market scans, VOC, and financial models to shape term sheets and negotiation options across stakeholders Delivered Results • Initiated $500M TAM market entry for a cloud-based solution for radiopharmaceutical extravasation mitigation; advanced pilot partnership with academic-biotech consortium and initiated in-licensing strategy. • Managed external partners to develop and scale enterprise AI/computer vision tools (25%+ growth CAGR) to optimize nurse adherence, reduce documentation, and enhance medication safety. • Journey mapped oncology center efficiency and other unserved unmet needs through value-stream mapping, clinician interviews, market scans, and feasibility pilots with health systems.

Conducted asymmetric due diligence and market research to define adjacencies for new growth revenue. Scaled internal venture for smart disposable solutions supporting IV medication administration in oncology and radiopharma centers. Delivered Results • Accelerated external pre-commercial-to-NPD progress for IV Flush innovation in existing workflow by guiding cross-functional teams, securing stakeholder alignment, and championing feasibility and business case development, driving a product now in pipeline with $33M projected revenue. • Expanded inorganic and organic 10-year pipeline value from $65 million to $460 million through strategic innovation, cross-functional collaboration, and data-driven DFSS, Jobs-to-be-Done, and Biodesign analyses.

Led global incubator and R&D due diligence & innovation for diagnostic and digital platforms across 7 international sites, building and scaling high-performing teams of 60+ employees while driving execution of annual business plans aligned with revenue and financial targets. Launched inorganic and organic lifecycle value-enhancing initiatives, including margin optimization and customer satisfaction programs. Guided strategy for cost reduction, clinical marketing, and global pricing execution. Reported to the CTO and served on multiple executive committees, providing strategic direction for medical device innovation, business development, operational execution, and cross-functional alignment. Top Contributions at Hillrom • Grew $100 million revenue stream through inorganic and organic diagnostic & sensing technology while keeping gross profit margins at 50%+. • Built 4 key organizations that fueled inorganic & organic growth and licensing while steering Hillrom’s purposeful global transformation. • Evolved organizational culture, progressing teams beyond their comfort zones for due diligence on riskier and more profitable concepts. • Partnered with pharma and academia to evaluate, license, and integrate digital biomarkers. • Guided cross-functional R&D, compliance, and go-to-market teams for digital solutions improving nurse workflow and safety outcomes Profitable Innovations • Led R&D due diligence and developed Hillrom’s first SaaS solution enabling earlier detection of sepsis risk by integrating real-time vitals and machine learning, reducing alert delays tied to stale EMR data, improving early intervention and enhancing Hillrom’s competitive position in clinical decision support. • Directed formation and acquisition-readiness of internal startup WatchCare, achieving $85M NPV and highest corporate valuation in 100-year history • Delivered commercial excellence with product managers by product differentiation through embedded sensing and smart features (e.g., autodocumentation of patient weighing subsystem in Accella beds → 39% revenue growth). • De-risked and advanced 6 back-end innovations into NPD, including load-cell weighing and algorithm-based breathing synchrony for airway clearance, driving 39% YoY growth of global bed platform and $30M launch-year sales of respiratory devices. Ascending the Ranks and Optimizing Capabilities Directed enterprise-wide innovation strategy and execution, leading four long-range roadmaps in collaboration with senior executives. Drove improvements in medical device safety and product development across distinct quality management systems (hardware, embedded software, algorithms, consumables). Championed engineering rigor, project management excellence, and pilot manufacturing. Mentored talent into senior leadership roles including VP Medical Affairs, Chief Scientist, CTO, and Data Scientist. • Spearheaded Hillrom’s first front-end innovation team, scaling from 3 to 13 innovators across the U.S. over 7 years. Led R&D initiatives that drove advancements in surgical robotic tables and next-gen hospital beds. • Revitalized and expanded the back-end innovation team into a global R&D unit of 12 engineers across the U.S., France, and Singapore. Reduced technical and business risk in early-stage technologies through standardized test protocols and robust user validation. Fostered cross-unit collaboration to design scalable business models and ensure end-user alignment. • Founded Hillrom’s first internal incubator in 2015, growing a 34-person startup team spanning electrical engineering, signal processing, smart disposables manufacturing, QA, and regulatory. Established the company’s Data Science Group in 2016, accelerating machine learning integration and predictive algorithm development across product lines.

Led P&L for GE’s Imaging Solutions CRO operations across the UK, Sweden, and Finland, managing a global team of 13 radio chemists and clinical research professionals supporting diagnostic imaging trials and pharma-sponsored research, including BMS, Merck, and GSK. Managed direct sales team (2 FTEs) and built commercial capabilities, pricing strategies, and customer development plans. Co-chaired the ISS Committee, collaborated with top cancer centers, and drove innovation by integrating radiochemistry, clinical research, and engineering to enhance device manufacturability and strategic direction. Delivered Results • Delivered 30% YoY revenue growth, scaling from $17M to $24.9M by optimizing capacity, sales force leadership, and service offerings in first-in-human and Phase I/II imaging studies following GCP and GMP for major pharma clients, including BMS, GSK, and Merck. • Managed direct sales team (2 FTEs) and built commercial capabilities, pricing strategies, and customer development plans, achieving fee-for-service expansion with major pharma clients. • Forged and managed 3 strategic alliances with ImaginAb, Medpace, and NeuroImage to enhance PET radiolabeling capabilities and meet biologics market demand, contributing to expanded service offerings and client acquisition.

Additional Relevant Experience GE Healthcare, Princeton and Piscataway, NJ Global Molecular Imaging Scientist Molecular Imaging Probes Applications Scientist and Reagents Product Manager GE Global Research Center, Niskayuna, NY Biochemist and Biomedical Physicist UCLA School of Medicine, Los Angeles, CA Graduate Student Researcher - Department of Medical and Molecular Pharmacology North American Scientific, North Hollywood, CA Laboratory Supervisor, Operations

Certifications • AI in Health Care: From Strategies to Implementation | HARVARD MEDICAL SCHOOL, Cambridge, MA • Graduate Certificate in Health Care Mission (audited) | AQUINAS INSTITUTE OF THEOLOGY, St. Louis, MO • Managing Innovation, Stanford Biodesign Exec. Education | STANFORD CENTER FOR BIODESIGN, Palo Alto, CA • Servant Leadership Certification | CORNELL UNIVERSITY, Ithaca, NY • Strategic Project Leader Certification | PROJECT MANAGEMENT INSTITUTE, Long Beach, CA • Six Sigma Green Belt Certification | GENERAL ELECTRIC, Niskayuna, NY